Outcomes for patients in the RESTORE registry with spinal muscular atrophy and four or more SMN2 gene copies treated with onasemnogene abeparvovec.
第一作者:
Eduardo F,Tizzano
第一单位:
Department of Clinical and Molecular Genetics, Hospital Vall d'Hebron, Passeig de la Vall d'Hebron, 119-129, Horta-Guinardó, 08035, Barcelona, Spain. Electronic address: eduardo.tizzano@vallhebron.cat.
作者:
主题词
人类(Humans);运动神经元生存蛋白质2(Survival of Motor Neuron 2 Protein);登记(Registries);男(雄)性(Male);婴儿(Infant);女(雌)性(Female);肌萎缩, 脊髓性(Muscular Atrophy, Spinal);生物制品(Biological Products);儿童, 学龄前(Child, Preschool);婴儿, 新生(Infant, Newborn);治疗结果(Treatment Outcome);基因剂量(Gene Dosage);重组融合蛋白质类(Recombinant Fusion Proteins)
DOI
10.1016/j.ejpn.2024.08.006
PMID
39260228
发布时间
2024-11-29
- 浏览0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文